Blueshift Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Blueshift Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,975	Closed	-$428K	–	453
2023 Q2	$428K	Buy	+1,975	New	+$423K	0.16%	154
2023 Q1	–	Sell	-2,424	Closed	-$476K	–	483
2022 Q4	$476K	Buy	+2,424	New	+$520K	0.22%	125
2021 Q4	–	Sell	-3,000	Closed	-$367K	–	1304
2021 Q3	$367K	Sell	3,000 -339	-10%	-$39.1K	0.02%	745
2021 Q2	$381K	Buy	+3,339	New	+$390K	0.02%	656
2021 Q1	–	Sell	-4,148	Closed	-$421K	–	1127
2020 Q4	$421K	Buy	+4,148	New	+$384K	0.05%	451

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Blueshift Asset Management's KRTX Position: Q3 2023 in Review

Blueshift Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,975 shares — an estimated $428K sold.

Blueshift Asset Management first reported a position in KRTX in Q4 2020 and held it in 5 quarters. The position peaked at $476K in Q4 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Blueshift Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Blueshift Asset Management sold 1,975 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $428K.
Blueshift Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Blueshift Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $476K in Q4 2022.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Blueshift Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.